•  
  •  
 

Article Type

Original Study

Abstract

Objective The aim of this work was to assess the clinical utility of Midkine (MDK) and Golgi protein 73 (GP73) among Egyptian hepatocellular carcinoma (HCC) patients in comparison with α-fetoprotein (AFP). Background Serum MDK and serum Golgi protein 73 (sGP73) are promising biomarkers for the detection of HCC. Patients and methods This study included 96 patients; 40 of them had proved HCC, 36 patients had chronic liver diseases and 20 apparently healthy individuals were considered as controls. Clinical examination, abdominal ultrasonography, and triphasic computerized tomography for focal lesion were performed. Liver function tests, hepatitis markers and serum AFP were measured. Serum MDK and GP73 levels were determined by enzyme-linked immunosorbent assay. Results There was a high statistically significant difference in MDK and GP73 between HCC and the control group. For the diagnosis of HCC, the receiver operating characteristic (ROC) curve showed that serum MDK and GP73 levels had an area under the receiver operating characteristic (AUROC) curve of (1.00, 0.952), sensitivity of (100%, 90%) and specificity of 88.9% and 83.3% at a cutoff point of 1585.0 pg/l, 42.5 ng/l, respectively. For early diagnosis of HCC, the ROC curve showed that the serum MDK and GP73 levels had the AUROC curve of 0.869 and 0.941, sensitivity of 88.9 and 94.4% and specificity of 79.5 and 83.3% at a cutoff point of 3825 pg/l and 84.5 ng/l, respectively. Conclusion MDK and GP73 serum levels are highly increased in HCC patients. Their diagnostic performance is superior to that of AFP.

Download

Share

COinS